Holen Sie sich die Stockscreener-App
2.02
0.49%
-0.010
Handel nachbörslich:
2.03
0.010
+0.50%
Schlusskurs vom Vortag:
$2.03
Offen:
$2.075
24-Stunden-Volumen:
240.44K
Relative Volume:
0.57
Marktkapitalisierung:
$188.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.60M
KGV:
67.33
EPS:
0.03
Netto-Cashflow:
$-62.91M
1W Leistung:
-7.34%
1M Leistung:
+31.17%
6M Leistung:
+32.03%
1J Leistung:
-10.62%
1-Tages-Spanne:
$1.975
$2.075
1-Wochen-Bereich:
$1.975
$2.205
52-Wochen-Spanne:
$1.13
$2.66
Compugen Ltd Stock (CGEN) Company Profile
Vergleichen Sie CGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.02 | 189.88M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-05-13 | Eingeleitet | Stifel | Buy |
| 2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-22 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
| 2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-23 | Fortgesetzt | Jefferies | Buy |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-02-07 | Eingeleitet | MLV & Co | Buy |
| 2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
Compugen (NASDAQ:CGEN) Stock Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Can Compugen Ltd. maintain sales growthHead and Shoulders Patterns & Small Budget Wealth Tips - bollywoodhelpline.com
Aug Opening: Can Fidelis Insurance Holdings Limited stock outperform in a bear marketRate Hike & Stepwise Trade Execution Plans - baoquankhu1.vn
Compugen (NASDAQ:CGEN) Stock Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Can Compugen Ltd maintain sales growthEarnings Growth Summary & Stock Portfolio Risk Management - baoquankhu1.vn
Update Recap: Can Compugen Ltd stock continue upward trendPortfolio Value Report & Smart Money Movement Alerts - Bộ Nội Vụ
Targets Report: Will Compugen Ltd stock outperform tech sector in 2025July 2025 Volume & High Win Rate Trade Tips - Bộ Nội Vụ
Compugen shares jump after $65 million royalty monetization deal with AstraZeneca - MSN
Why Compugen Ltd. stock could benefit from AI revolutionRate Cut & Intraday High Probability Alerts - Улправда
Brokers Issue Forecasts for Compugen FY2025 Earnings - Defense World
HC Wainwright Estimates Compugen FY2025 Earnings - MarketBeat
Comparing Compugen (NASDAQ:CGEN) & Psyence Biomedical (NASDAQ:PBM) - Defense World
Compugen (NASDAQ:CGEN) Coverage Initiated at HC Wainwright - Defense World
Compugen rises on royalty deal with AstraZeneca - MSN
How buybacks impact Compugen Ltd. stock valueRate Hike & Capital Efficiency Focused Strategies - Улправда
Why Compugen Ltd. stock could rally in 2025Quarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда
Will Compugen Ltd. stock benefit from infrastructure spending2025 Dividend Review & Low Volatility Stock Suggestions - Улправда
Compugen (NASDAQ:CGEN) Stock Rating Upgraded by HC Wainwright - MarketBeat
Is Compugen Ltd. stock a bargain at current levelsMoving Average Strategies & Expert-Backed Recommendations That Deliver - Улправда
H.C. Wainwright initiates coverage on Compugen stock with Buy rating By Investing.com - Investing.com Nigeria
Compugen (CGEN): HC Wainwright Initiates Coverage with 'Buy' Rat - GuruFocus
H.C. Wainwright initiates coverage on Compugen stock with Buy rating - Investing.com
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of Compugen (CGEN) with Buy Recommendation - Nasdaq
Operating cash flow per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Will Compugen Ltd. stock benefit from sector rotationWeekly Profit Summary & Daily Growth Stock Tips - Улправда
Is Compugen Ltd. stock a defensive play in 2025Portfolio Gains Summary & Real-Time Volume Analysis Alerts - Улправда
Can Compugen Ltd. stock deliver strong Q4 earningsJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - Улправда
Compugen stock soars on $65 million AstraZeneca royalty deal By Investing.com - Investing.com Australia
Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca - TipRanks
Compugen (CGEN) Rises on Royalty Deal with AstraZeneca - GuruFocus
Compugen restructures AstraZeneca deal to boost cash coffers - גלובס
Compugen stock soars on $65 million AstraZeneca royalty deal - Investing.com
Compugen Monetizes Portion of Cancer Treatment Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha
Compugen monetizes portion of cancer drug royalties to AstraZeneca By Investing.com - Investing.com South Africa
Compugen monetizes portion of cancer drug royalties to AstraZeneca - Investing.com
Compugen monetizes portion of rilvegostomig future royalties to AstraZeneca for up to $90 million - marketscreener.com
Compugen Ltd. and Medimmune Limited Enter into Amendment Number 4 to the License Agreement - marketscreener.com
Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million - TradingView — Track All Markets
[6-K] COMPUGEN LTD Current Report (Foreign Issuer) | CGEN SEC FilingForm 6-K - Stock Titan
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
Cancer immunotherapy royalty deal brings biotech up to $90M in funding - Stock Titan
Revenue per share of Compugen Ltd. – TASE:CGEN - TradingView — Track All Markets
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):